BRAF and metastatic neoplasm: Similarly, our study found that the frequencies of EGFR, KRAS, HER2, BRAF, and PIK3CA mutations in TKI‐naive samples and the frequencies of sensitizing EGFR and T790M mutations in TKI‐relapsed samples showed no statistical differences between unpaired primary and metastatic tumors.